Method for removing deposits from chemical reactors
    1.
    发明授权
    Method for removing deposits from chemical reactors 失效
    从化学反应堆中去除沉积物的方法

    公开(公告)号:US06986816B2

    公开(公告)日:2006-01-17

    申请号:US10484179

    申请日:2002-07-08

    IPC分类号: B08B7/00

    摘要: The invention relates to a process for the removal of deposits formed in a reaction apparatus by the precipitation of solids from a liquid reaction mixture, which process is characterized in that particles of a material that is inert under the reaction conditions are introduced into the reaction apparatus, which particles, by suitable mechanical circulation of the reaction mixture, are so moved through the reactor that, during the reaction, by striking the walls or other built-in elements, they abrasively remove precipitates adhered thereto.

    摘要翻译: 本发明涉及一种通过从液体反应混合物中沉淀固体而去除在反应装置中形成的沉积物的方法,该方法的特征在于在反应条件下将惰性物质的颗粒引入反应装置 通过反应混合物的适当的机械循环将颗粒移动通过反应器,在反应过程中,通过撞击壁或其它内置元件,它们可以磨蚀地去除附着在其上的沉淀物。

    Orally administered pharmaceutical agent for iron and magnesium
substitutive therapy
    3.
    发明授权
    Orally administered pharmaceutical agent for iron and magnesium substitutive therapy 失效
    ORALLY ADMINISTERED PHARMACEUTICAL AGENT FOR IRON AND MAGNESIUM SUBSTITUTIVE THERAPY

    公开(公告)号:US5143732A

    公开(公告)日:1992-09-01

    申请号:US323993

    申请日:1989-03-15

    IPC分类号: A61K33/26

    CPC分类号: A61K33/26

    摘要: An orally administered pharmaceutical agent that is particularly suited for iron and magnesium substitutive therapy is disclosed. This drug consists of a combination of one or more pharmaceutically and physiologically compatible iron compounds, one or more pharmaceutically and physiologically compatible magnesium compounds, and, if the magnesium compounds do not contain any chlorine atoms dissociable in aqueous media and saturating the available magnesium valences, the drug further consists of one or more pharmaceutically and physiologically compatible compounds providing chlorine ions in aqueous media. The iron compounds, magnesium compounds and chlorine ion supplying compounds may be mixed with the conventional pharmaceutical solvents and/or thinners and/or auxiliary matter. Unexpectedly, this drug makes it possible to simultaneously administer magnesium or calcium compounds with iron compounds, without thereby causing reduced iron resorption.

    摘要翻译: 公开了特别适用于铁和镁替代疗法的口服给药药物。 该药物由一种或多种药学和生理相容的铁化合物,一种或多种药学和生理学上相容的镁化合物的组合组成,并且如果镁化合物不含有在水性介质中可解离并使饱和可用的镁价的任何氯原子, 药物还包含一种或多种在水性介质中提供氯离子的药学和生理学上相容的化合物。 铁化合物,镁化合物和氯离子供给化合物可以与常规药物溶剂和/或稀释剂和/或辅助物质混合。 出乎意料的是,该药使得可以用铁化合物同时施用镁或钙化合物,而不会引起铁吸收减少。

    Sedative preparation for animals and method
    4.
    发明授权
    Sedative preparation for animals and method 失效
    动物镇静剂及方法

    公开(公告)号:US4192865A

    公开(公告)日:1980-03-11

    申请号:US900568

    申请日:1978-04-27

    申请人: Joachim Helbig

    发明人: Joachim Helbig

    摘要: The invention concerns sedative preparations suitable for calming of animals and a method of sedating a warm-blooded animal other than human, comprising the step of administering to such a warm-blooded animal which it is desired to sedate, a magnesium aminodicarboxylic acid chloride, or a magnesium salt of an aminodicarboxylic acid in combination with magnesium chloride, at a dosage sufficient to sedate said warm-blooded animal.

    摘要翻译: 本发明涉及适用于镇静动物的镇静制剂和镇静除人之外的温血动物的方法,包括给予需要镇静的这种温血动物施用步骤,氨基二羧酸氯化镁或 氨基二羧酸的镁盐与氯化镁组合,其用量足以镇静所述温血动物。

    Method for the prophylaxis of cardiac infarctions and the prevention of
reinfarctions
    5.
    发明授权
    Method for the prophylaxis of cardiac infarctions and the prevention of reinfarctions 失效
    预防心脏梗死和预防再梗塞的方法

    公开(公告)号:US5006516A

    公开(公告)日:1991-04-09

    申请号:US345276

    申请日:1989-05-01

    IPC分类号: A61K33/14

    摘要: The invention relates to an agent for the prophylaxis of cardiac infarcti and for the prevention or reinfarctions, and is characterized by the fact that said agent comprises a combination of magnesium amino dicarboxylic acid halides, basic magnesium amino dicarboxylic acid salts, and magnesium halides, singly or in combination, on the one hand, and acetylsalicylic acid, on the other hand, as well as conventional pharmaceutical carriers, diluents, and/or adjuvants, as required.

    摘要翻译: 本发明涉及一种用于预防心脏梗塞和预防或再梗死的药剂,其特征在于所述药物包括镁氨基二羧酸卤化物,碱性镁氨基二羧酸盐和卤化镁的组合,单独 另一方面,或者一方面,组合,和乙酰水杨酸,以及常规药物载体,稀释剂和/或佐剂,根据需要。

    Process for the production of amino-dicarboxylic acid-bivalent
metal-halogen complexes and such complexes
    6.
    发明授权
    Process for the production of amino-dicarboxylic acid-bivalent metal-halogen complexes and such complexes 失效
    制备氨基二羧酸二价金属卤素络合物和这种络合物的方法

    公开(公告)号:US4546195A

    公开(公告)日:1985-10-08

    申请号:US540644

    申请日:1983-10-11

    IPC分类号: C07F3/00 C07F13/00 C07F3/06

    CPC分类号: C07F13/005 C07F3/003

    摘要: The invention concerns a novel process for the production of a complex cound comprising an amino-dicarboxylic acid ion component, a bivalent metal ion component, and a halogen ion component, which comprises the step of reacting together in an aqueous medium an amino-dicarboxylic acid compound, a bivalent metal compound, and a halogen compound, the proportions of said compounds being chosen so that one of each of said ion components is comprised in the aqueous medium, the bivalent metal compound being selected from the oxide, hydroxide, carbonate or a halide of the bivalent metal, and the halogen compound being said halide of the bivalent metal or a hydrogen halide. Certain of the complexes are novel and find use in a variety of medical and veterinary fields.

    摘要翻译: 本发明涉及一种制备包含氨基二羧酸离子组分,二价金属离子组分和卤素离子组分的络合物的新方法,其包括在水性介质中一起在氨基二羧酸 化合物,二价金属化合物和卤素化合物,所述化合物的比例选择为使得每种所述离子组分中的每一种包含在水性介质中,所述二价金属化合物选自氧化物,氢氧化物,碳酸盐或 二价金属的卤化物,卤素化合物是二价金属的卤化物或卤化氢。 某些复合物是新颖的,可用于各种医学和兽医领域。

    Magnesium-containing pharmaceutical compositions
    7.
    发明授权
    Magnesium-containing pharmaceutical compositions 失效
    含镁药物组合物

    公开(公告)号:US4041154A

    公开(公告)日:1977-08-09

    申请号:US658717

    申请日:1976-02-17

    CPC分类号: A61K33/14 A61K33/06

    摘要: The invention concerns magnesium-containing pharmaceutical compositions comprising at least one of magnesium diglutamate and magnesium diaspartate and one or more alkali or alkaline earth metal halogenide such as magnesium chloride, bromide or iodide, sodium or potassium chloride, bromide or iodide and calcium chloride, bromide or iodide. Combinations comprising lithium chloride or bromide and strontium chloride or bromide are also disclosed. The combinations are intended for use in raising magnesium levels in plasma and bone structures in warm blooded mammals.

    摘要翻译: 本发明涉及含镁药物组合物,其包含谷氨酸镁和二天冬氨酸镁中的至少一种和一种或多种碱金属或碱土金属卤化物如氯化镁,溴化物或碘化物,氯化钠或氯化钾,溴化物或碘化物和氯化钙,溴化物 或碘化物。 还公开了包含氯化锂或溴化物和氯化锶或溴化锶的组合。 这些组合旨在用于提高温血哺乳动物血浆和骨骼结构中的镁含量。